China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
23.7
38.93
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
China Resources Boya Bio pharmaceutical Group Co Ltd
China Resources Boya Bio pharmaceutical Group Co Ltd
Net Issuance of Debt
China Resources Boya Bio pharmaceutical Group Co Ltd
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
|
Net Issuance of Debt
-¥22.1m
|
CAGR 3-Years
55%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Net Issuance of Debt
¥2.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Net Issuance of Debt
¥1.1B
|
CAGR 3-Years
219%
|
CAGR 5-Years
105%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Net Issuance of Debt
¥38m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Net Issuance of Debt
-¥2.6m
|
CAGR 3-Years
30%
|
CAGR 5-Years
72%
|
CAGR 10-Years
28%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Net Issuance of Debt
¥358.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
China Resources Boya Bio pharmaceutical Group Co Ltd
Glance View
Boya Bio-pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of blood products. The company is headquartered in Fuzhou, Jiangxi and currently employs 1,652 full-time employees. The company went IPO on 2012-03-08. The firm's main products include human albumin, freeze-drying intravenous injection human immune globulin, human immune globulin, hepatitis B human immune globulin, hydrophobia human immune globulin, human fibrinogen, metformin hydrochloride, calcium dobesilate capsules, glimepiride and pioglitazone hydrochloride dispersible tablets, among others. The firm's blood products are mainly used in the treatment of tumor, liver diseases and diabetes, among others. The firm also provides diabetic pharmaceuticals and biochemical pharmaceuticals. The firm distributes its products mainly in domestic market.
See Also
What is China Resources Boya Bio pharmaceutical Group Co Ltd's Net Issuance of Debt?
Net Issuance of Debt
-22.1m
CNY
Based on the financial report for Sep 30, 2024, China Resources Boya Bio pharmaceutical Group Co Ltd's Net Issuance of Debt amounts to -22.1m CNY.
What is China Resources Boya Bio pharmaceutical Group Co Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 5Y
42%
The average annual Net Issuance of Debt growth rates for China Resources Boya Bio pharmaceutical Group Co Ltd have been 55% over the past three years , 42% over the past five years .
You don't have any saved screeners yet
